After years of R&D efforts VAR2 Pharma is finally ready to present its novel proprietary cancer targeting antibodies. The antibodies targeting oncofetal chondroitin sulfate have demonstrated very high broad solid tumor specificity and preclinical PoC for antibody-drug conjugate (ADC) applications in different cancer disease models. These antibodies are also being deployed in the VarCT Diagnostics […]
Menu